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A series of 1,4-substituted arylalkyl piperazine derivatives were synthesized and studied with the 
aim to obtain potent P-gp-dependent multidrug-resistant (MDR) reversers. The new compounds 
were designed on the basis of the structures of our previous arylamine ester derivatives endowed 
with high P-gp-dependent multidrug resistance reversing activity. All new compounds were active 
in the pirarubicin uptake assay on the doxorubicin–resistant erythroleukemia K562 cells 
(K562/DOX). In particular, compounds bearing methoxy aromatic moieties showed fairly high 
reversal activities. The most potent compounds, 8, 9, 10 and 13, were further studied by evaluating 
their doxorubicin cytotoxicity enhancement (reversal fold, RF) and the inhibition of P-gp-mediated 
rhodamine-123 (Rhd 123) efflux on the K562/DOX cell line. The results of all pharmacological 
assays indicated that the combination of a basic piperazine scaffold with arylalkyl residues allowed 
us to obtain very interesting P-gp modulating compounds. Two long-lasting P-gp pump modulators 
(9 and 10) were identified; they were able to inhibit remarkably the P-gp substrate rhodamine-123 
efflux on the resistant K562/DOX cell line after 60 min. Overall compound 9 appeared the most 
promising compound being a potent and long-lasting P-gp–dependent MDR modulator. 
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The success of the anticancer chemotherapy is frequently impaired by drug resistance that is the 
main defense mechanism that the tumor cells develop against chemotherapeutic drugs. Multidrug 
resistance (MDR) is a type of acquired drug resistance to multiple classes of structurally and 
mechanistically unrelated anticancer drugs [1]. The cells exhibiting MDR accumulate a lower 
intracellular concentration of drug as a result of an accelerated efflux of the antitumor agents 
mediated by an ATP-dependent process. The main mechanism responsible of this transport is the 
overexpression of ABC (ATP Binding Cassette) transmembrane proteins such as P-glycoprotein (P-
gp, ABCB1), the multidrug-resistance-associated protein-1 (MRP1, ABCC1) and the breast cancer 
resistance protein (BCRP, ABCG2). 
Circumvention of multidrug resistance through the inhibition of the functions of ABC proteins is 
considered an important field of investigation. MDR reversers (chemosensitizers) are compounds 
that co-administrated with cytotoxic agents, which are ABC proteins substrates, allow the restoring 
of their efficacy in resistant cancer cells [2,3]. 
P-glycoprotein is the most studied of the ABC transporters. It is a membrane glycoprotein 
expressed in several important tissues and blood-tissue barriers where it plays important 
physiological roles as the regulation of the secretion of lipophilic molecules and the extrusion of 
exogenous toxic agents that enter the organism [4,5]. Nevertheless, P-gp is overexpressed in cancer 
cells as a result of an upregulation of the human gene expression MDR1 that causes an accelerated 
efflux of the chemotherapeutic drugs inducing the classical multidrug resistance (MDR) [6-8]. 
In the last decades many P-gp modulators
, 
belonging to three generations of compounds have been 
identified. A few of them have reached clinical trials [9-11], nevertheless, no drug has been 
approved for therapy. In fact, the development of safe MDR reversers is complicated by the P-gp 
physiological roles and the concurrent inhibitory action of these compounds on isoforms of 
cytochrome, like CyP3A4. Therefore, they could interfere with the pharmacokinetics of other 
substances, including the co-administered chemotherapeutic agents [12]. Thus, an ideal MDR 
reverser should be a potent and selective P-gp modulator without affecting the cytochrome activity.  
The latest MDR reversing compounds, in addition to high potency and low toxicity, show a good 
specificity for P-gp displaying no pharmacokinetic interaction with chemotherapeutic drugs [13]. In 
particular, the third generation P-gp modulator Zosuquidar is a potent and selective P-gp inhibitor 
with almost no interaction with the multidrug-resistance-associated protein-1 (MRP1) or the breast 
cancer resistance protein (BCRP) and little effect on CyP3A4 [10]. 
Zosuquidar structure is characterized by the presence of a piperazine scaffold that is present also in 
other important MDR reversers as Dofequidar [14] (Chart 1). These compounds contain many of 
the features considered important for P-gp interaction, such as high lipophilicity, the presence of 




Chart 1. Third generation P-gp modulators 
 
For many years our research group has been involved in the design and synthesis of several P-
glycoprotein (P-gp) ligands with the aim to discover potent MDR modulators. Their structures are 
related to those of the tropane alkaloid pervilleine A, endowed with good MDR modulating activity 
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[16], and the first generation modulator verapamil (Chart 2). Therefore these molecules are 
characterized by the presence of a basic nitrogen flanked at suitable distance by aromatic moieties 
The majority of these molecules are arylamine ester derivatives, so they contain aromatic ester 
residues, likewise pervilleine A, linked to a basic scaffold by polymethylenic chains or cyclohexylic 
moieties, with different flexibility (Chart 2, structure I). Most of these compounds have proven to 
be potent and efficacious P-gp-dependent multidrug resistance reversers [16-20]. The ester 
functions present in these molecules may be susceptible to enzymatic hydrolysis; therefore, to avoid 
any possible problem associated with the metabolic lability of this group, in the present study we 
report the synthesis and preliminary pharmacological properties of a new series of derivatives 
carrying a piperazine nucleus as basic scaffold, and different arylalkyl groups on the two nitrogen 




Chart 2. Structures of lead and designed compounds 
 
These compounds were designed on the basis of the above mentioned structural requirements that 
are considered important for P-gp interaction (Chart 3). Therefore, aromatic substituents were 
chosen such as the cinnamyl (a), the 2-phenoxyethyl (b), the 2-isopropyl-2-phenylpentanenitrile (c) 
and the 4,4-diphenylbutyl (d) groups, that contain unsubstituted phenyl rings. The corresponding 
methoxylated moieties g, h, i, l, respectively, were inserted to evaluate the role of the hydrogen 
bond acceptor methoxy group, that is considered important for the MDR-reversing activity and is 
present in many well-known P-gp modulating compounds [9]. For the same reason the 3,4,5-
trimethoxybenzyl group (m) was also inserted. The nucleus e was chosen to investigate the 
importance of the presence of fluorine, and the 9-methylanthracene nucleus f because it was present 
in compounds previously studied that proved to be very potent multidrug resistance reversers [16-
18]. 
The reversal activity of the new compounds was evaluated in a preliminary screening by the 
pirarubicin uptake assay on doxorubicin-resistant erythroleukemia K562 cells. The pharmacological 
profile of the most potent compounds, 8, 9, 10 and 13, was further studied by evaluating their 
doxorubicin cytotoxicity enhancement (reversal fold, RF) and the inhibition of P-gp-mediated 
rhodamine-123 (Rhd 123) efflux on the K562/DOX cell line. 
In addition, an investigation about the stability of derivatives 8, 9, 10 and 13 was performed by 
evaluating the concentration of their solutions in phosphate buffer solution (PBS) at different 
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incubation times. Moreover, the behaviour of these compounds in the presence of rat and human 
plasma was also studied to establish the actual concentration in biological conditions. In fact, their 









The reaction pathways used to synthesized piperazine derivatives 1-13, are described in Scheme 1. 
Reaction of N-t-BOC-piperazine [21] with the suitable arylalkyl halide in CH3CN under basic 
conditions (K2CO3) gave compounds 15-19. The arylalkyl halides are commercially available ((E)-
(3-bromoprop-1-enyl)benzene) or were synthesized according to the literature (5-bromo-2-
isopropyl-2-phenyl-pentanenitrile [22], 2-bromoethoxy benzene [22] and 9-
(chloromethyl)anthracene [23]). The arylalkyl halide 5-(2-bromoethoxy)-1,2,3-trimethoxybenzene 
(14), used to synthesize compound 19, was obtained by reaction of 3,4,5-trimethoxyphenol with 
1,2-dibromoethane in anhydrous DMF, in a different way with respect to Drain [24] (Scheme 2). 
Finally, compound 20 was obtained by reaction of N-t-BOC-piperazine [21] with (E)-3-(3,4,5-
trimethoxyphenyl)prop-2-en-1-ol [25] in the presence of CH3SO2Cl and anhydrous Et3N, in 
anhydrous CH2Cl2. Cleavage of the protective group was performed with CF3COOH to obtain 
compounds 21-26. These intermediates, together with 1-(3,4,5-trimethoxybenzyl)piperazine 27, 
already described [26], were N-alkylated with the suitable arylalkyl halide and K2CO3 in CH3CN to 
yield final compounds 1-13. The arylalkyl halides are mentioned above or synthesized according to 
the literature (1-bromo-4,4-diphenylbutane [27], 1-bromo-4,4-bis(4-fluorophenyl)butane [28], 5-
bromo-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile [29], 1-bromo-4,4-bis(4-







Scheme 1. Reagents and conditions: (i) ArBr or ArCl, K2CO3, CH3CN, or (E)-3-(3,4,5-trimethoxyphenyl)-prop-2-en-1-
ol [25], CH3SO2Cl, anhydrous Et3N, anhydrous CH2Cl2; (ii) CF3COOH, CH2Cl2; (iii) Ar1Br or Ar1Cl, K2CO3, CH3CN. 
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Scheme 2. Reagents and conditions: (i) BrCH2CH2Br, K2CO3, anhydrous DMF. 
 
3. Results and discussion 
 
3.1. Modulation of pirarubicin uptake  
 
The P-gp modulating ability of compounds 1-13 was evaluated on K562/DOX doxorubicin resistant 
cells that overexpress only the membrane glycoprotein P-gp [32-34]. K562 is a human leukemia 
cell line established from a patient with chronic myelogenous leukemia in blast transformation [35]. 
The uptake of THP-adriamycin (pirarubicin) was measured by a continuous spectrofluorometric 
signal of anthracycline at 590 nm (ex = 480 nm) after cell incubation, following the protocols 
reported in previous papers [29,36]. The P-gp modulating activity of the studied compounds on the 
pirarubicin uptake test is expressed by: i) [I]0.5, which measures the potency of the modulator and 
represents the concentration that causes a half-maximal increase (= 0.5) in the nuclear 
concentration of pirarubicin, and ii) max, which represents the efficacy of the modulator and is the 
maximum increase in the nuclear concentration of pirarubicin in resistant cells that can be obtained 
with a given compound. The value of  varies between 0 (in the absence of the modulator) and 1 
(when the amount of pirarubicin in resistant cells is the same as in sensitive cells).  
The results obtained are reported in Table 1 together with those of verapamil, the gold standard of 
P-gp activity inhibition, used as reference compound. All the newly synthesized compounds were 
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able to inhibit the activity of P-gp and their potencies and efficacies were higher than those of 
verapamil, with the exception of compound 5 which was as potent as verapamil. All molecules 
showed potency values ([I]0.5) in the submicromolar range and were able to completely reverse P-
gp-dependent pirarubicin extrusion (max close to 1), except compound 5.  
These results fulfill our expectations on the positive effect of the presence of the piperazine scaffold 
on the P-gp modulating activity. In general, compounds bearing methoxy aromatic moieties (6-13) 
showed higher potencies than those lacking the methoxy groups (1-5). In particular, compounds 8, 
9, 10 and 13 displayed an outstanding activity in the nanomolar range ([I]0.5 = 0.01, 0.09, 0.03 and 
0.06 μM, respectively). The most active compounds have the 4,4-bis(4-methoxyphenyl)butyl 
moiety (l) combined with h, g and m residues (compounds 8, 9 and 10, respectively) or the 9-
(methyl)anthracene moiety (f) combined with the (E)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-yl 
group (g) (compound 13). The presence of fluorine as substituent on the aromatic rings (see moiety 
e), appears to be not positive for the activity, in fact compound 5 was nearly 6 times less potent than 
the non-substituted compound 4 ([I]0.5 = 1.71 and 0.28 μM, respectively). 
These results are not unexpected since methoxy substituted aromatic residues were present in the 
most active compounds of the previously synthesized series [16-20], as well as in pervilleine A and 
verapamil. In fact, the activity values of compounds 8, 9, 10 and 13 ([I]0.5 = 0.01-0.09 M and max 
= 0.90-0.99), that contain a combination of f, g, h, l and m residues, are within the same values of 
the most potent diester compounds of the polymethylenic or cyclohexylic series characterized by 
the presence of these aromatic residues. These results proved that the removal of the ester function 
of our previous derivatives did not compromise the good P-gp inhibitory activity of this new series 
of compounds  
 
Table 1  
MDR-reversing activity of compounds 1-13. 
 



















































verapamil   1.60±0.30 0.70±0.07 
 
a 
Concentration of the modulator that causes a 50% increase in nuclear concentration of pirarubicin (= 0.5). m
b 
Efficacy of MDR-modulator and maximum increase that can be obtained in the nuclear concentration of pirarubicin in 
resistant cells. Results are expressed as the mean  SE of three independent experiments done at least three times.  
 
3.2. Effects on doxorubicin cytotoxicity 
 
The most interesting compounds in the pirarubicin uptake test, 8, 9, 10 and 13, were further studied 
to assess their ability in the enhancement of doxorubicin cytotoxicity on the resistant K562/DOX 
cell line. The compounds were studied at 0.1, 1.0 and 3.0 µM concentrations in the absence of 
doxorubicin to evaluate their intrinsic cytotoxicity on both K562 and K562/DOX cell lines, using 
the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay [37].
 
At the three 
concentrations tested the compounds had no intrinsic toxicity on the parental and resistant cell lines, 
except compound 10 which showed an intrinsic toxicity, not exceeding 30%, at 3.0 µM 
concentration on the resistant cell line (data not shown). The MDR-reversal activity of the four 
compounds was evaluated in the presence of doxorubicin on both cell lines, at the same three 
concentrations. 
Figure 1 shows the cytotoxicity curves related to the effects of doxorubicin alone and in 
combination with compounds 8, 9, 10 and 13, at 1.0 µM concentration, on K562-parental cells (A) 
and the K562/DOX-resistant subline (B). 
As shown in Figure 1A, the compounds did not change the IC50 value of doxorubicin on the 
parental cell line. Instead, in the resistant cell line they were able to decrease the IC50 value of 
doxorubicin restoring its cytotoxicity (Figure 1B). These results indicate that these compounds have 


































Figure 1. Cytotoxicity curves related to the effects of doxorubicin alone and in combination with compounds 8, 9, 10 
and 13, at 1.0 µM concentration, on K562-parental cells (A) and K562/DOX-resistant subline (B). Each point of the 
curves is the mean ± SE of individual points determined in at least three experiments performed in quadruplicate. 
 
The IC50 values of doxorubicin tested alone and in combination with compounds 8, 9, 10 and 13, on 
the K562/DOX cell line were shown in Table 2. The reversal-fold (RF) values, which indicate the 
MDR reverser potency of the tested compounds, are also reported. The RF values were obtained as 
the ratio between the doxorubicin IC50 values on K562/DOX cells in the absence and in presence of 
modulators. At the three concentrations tested (0.1, 1.0 and 3.0 µM), the four compounds caused no 
significant modification of the doxorubicin IC50 value (0.022 ± 0.004 μM) in the parental 
doxorubicin sensitive K562 line (data not shown). 
Verapamil and the third generation chemosensitizer tariquidar, tested at 3.0 and 1.0 µM 
concentrations, respectively, were used as reference compounds. 
 
Table 2 
Effects of compounds 8, 9, 10 and 13 on doxorubicin cytotoxicity on K562/DOX cells, at 0.1, 1.0 
and 3.0 µM concentrations. 
 





































 DOX +  9   1.0 µM 
 DOX + 10  1.0 µM   
DOX + 13  1.0 µM 





DOX 2.20 ± 0.060
 
 
DOX + 8 (0.1 μM) 0.91 ± 0.005
c
 2.4 
DOX + 8 (1.0 μM) 0.49± 0.020
c
 4.5 
DOX + 8 (3.0 μM) 0.25± 0.050
c
 8.8 
DOX + 9 (0.1 μM) 1.14 ± 0.570
c
 1.9 
DOX + 9 (1.0 μM) 0.17 ± 0.050
c 
12.9 
DOX + 9 (3.0 μM) 0.05 ± 0.008
c 
44.0 
DOX + 10 (0.1 μM) 1.87 ± 0.130
 
1.2 
DOX + 10 (1.0 μM) 0.21 ± 0.060
c
 10.5 
DOX + 10 (3.0 μM) 0.03 ± 0.008
c 
73.3 
DOX +13 (0.1 μM) 1.28 ± 0.069
 
1.7 
DOX + 13 (1.0 μM) 0.25 ± 0.056
c
 8.8 
DOX + 13 (3.0 μM) 0.10 ± 0.019
c 
22.0 
DOX + verapamil (3.0 μM) 0.74 ± 0.020
c
 3.0 





 Mean ± SE of at least three determinations performed with quadruplicate cultures at each drug concentration tested 
and measured as described in Experimental section; 
b 
Values of reversal fold (RF) of MDR obtained as the ratio 
between the doxorubicin IC50 value on K562/DOX cells in the absence and in presence of modulators;
 c
 p < 0.05 vs 
control doxorubicin-treated. 
 
As reported in Table 2, these compounds were able to restore a high cytotoxic effect of doxorubicin 
in the resistant cell line, showing concentration-dependent activities. All compounds had scarce 
activity at 0.1 µM concentration showing RF values ranging between 1.2 and 2.4, however at 1.0 
µM and 3.0 µM concentrations they showed remarkable RF values. 
Actually, the concentration-dependent activity of compound 8 was not very pronounced since its RF 
values at 0.1, 1.0 and 3.0 µM concentrations were 2.4, 4.5 and 8.8, respectively. Compounds 9, 10 
and 13 showed similar RF values at 1.0 µM concentration (12.9, 10.5 and 8.8, respectively) 
whereas, at 3.0 µM concentration, the values were quite different (44.0, 73.3, 22.0, respectively) 
and the most potent compound, at this concentration, appears to be derivative 10 with a RF value of 
73.3. In any case it should be considered that this compound showed, at the same concentration, 
some intrinsic cytotoxicity toward the resistant cell line. All compounds were more potent than 
verapamil, tested at 3.0 µM concentration, but less potent than tariquidar at 1.0 µM concentration; 
in fact, its RF value is higher than those of the four compounds at the same concentration. 
 
3.3. Inhibition of P-gp-mediated rhodamine-123 (Rhd 123) efflux 
 
The ability of compounds 8, 9, 10 and 13 to inhibit the transport activity of the pump were 
measured using the P-gp specific substrate rhodamine-123 on the resistant K562/DOX cell line, 
following a previously described method with minor modifications [20]. The efflux of the 
fluorochrome was evaluated at two different times, 30 and 60 min, both in the presence and in 
absence of modulators at 1.0 μM concentration. On the parental cell line (K562), the studied 
compounds did not affect the fluorescence intensity, both in the accumulation and in the efflux 
phase, that was equal to that of the untreated control (data not shown).  
The inhibition of P-gp-mediated Rhd 123 efflux of compounds 8, 9, 10 and 13 on K562/DOX cells 




Figure 2A shows the mean fluorescence intensity (MFI) ratio values of compounds 8, 9, 10 and 13, 
at 30 and 60 min of efflux (table and histograms), obtained as the ratio between the median 
fluorescence intensity value of samples treated with modulators, and the untreated control sample, 
as reported in the Experimental Section. MFI ratio values near the unit were indicative of absence 
of modulation, values greater than 1 represented inhibition of pump activity due to the presence of 
the compounds. 
The MFI ratio values showed that all the tested compounds were able to inhibit the efflux of Rhd 
123 at both efflux times, to different extent. The most potent compounds were 9 and 10 that were 
able to increase the Rhd 123 intracellular fluorescence at 30 min, by nearly 100 and 30 times, 
respectively. Remarkable MFI ratio values were showed also at 60 min, since these two compounds 
were able to maintain a Rhd 123 intracellular fluorescence by 50 and 10 times, respectively, higher 
than the untreated control.   
All compounds tested at 1.0 μM concentration, were more potent than verapamil, tested at the 
concentration of 3.0 μM, at both efflux times. In fact, the increase of the Rhd 123 intracellular 
fluorescence, at 30 min, of compounds 8 and 13 was two or three times higher than verapamil (MFI 
ratio = 5.5, 7.5 and 2.3, respectively); after 60 min the Rhd 123 intracellular fluorescence in the 
cells treated with verapamil is the same as the control (MFI ratio = 1.0), while compounds 8 and 13 
were still able to inhibit the efflux since their MFI ratio values were 1.4 and 2.4, respectively. 
Figure 2B shows the fluorescence curves corresponding to the Rhd 123 uptake after 30 min of 
incubation, and to the Rhd 123 efflux after 60 min in Rhd 123-free medium, in the absence (panel a) 
and in presence of verapamil or the studied compounds (panels b-f). 
The treatment with verapamil and compounds 8, 9, 10 and 13, caused a Rhd 123 intracellular 
retention higher than the untreated control, since the corresponding curves (red) were shifted to the 
right respect to the curve of the control (green). Compounds 9 and 10 showed a higher shift of the 
curves than compounds 8 and 13, and all four compounds were more potent than verapamil in the 
accumulation phase. 
The fluorescence curves corresponding to the Rhd 123 efflux showed that compounds 8, 9, 10 and 
13 were able to inhibit the pump even after 60 min in Rhd 123-free medium, whereas verapamil 
caused an intracellular amount of Rhd 123 similar to the control (as also shown in Figure 2A). In 
the case of compounds 9 and 10, the curves were less shifted to the left, indicating a higher 
retention of the intracellular fluorescence. 
The results obtained suggested that the four studied compounds were able to modulate the transport 
activity of the P-gp through a long duration pump inhibition; in particular, compounds 9 and 10 




















 MFI ratio 
Comp. 30 min 60 min 
8 5.5±0.5 1.4±0.1 
9 107.9±12.6 49.9±13.0 
10 30.0±4.4 11.1±4.5 
13 7.5±2.1 2.4±0.70 
Ver. 2.3±0,.2 1.0±0.01 
Efflux time 



























Figure 2 Inhibition of P-gp-mediated Rhd 123 efflux of compounds 8, 9, 10 and 13 on K562/DOX cells. (A) Mean 
fluorescence intensity (MFI) ratio values in K562/DOX cells incubated with Rhd 123 in the presence of compounds 8, 
9, 10 and 13, tested at 1.0 μM concentration, and verapamil tested at 3.0 μM concentration. The data were calculated at 
two different efflux times, 30 and 60 min, as reported in the Experimental Section, and expressed as the mean ± SE of 
three independent experiments done at least three times. (B) Effects of compounds 8, 9, 10 and 13, tested at 1.0 μM 
concentration, on Rhd 123 uptake and efflux in K562/DOX cells. The fluorescence curves corresponding to the Rhd 
123 efflux were calculated after 60 min of incubation in Rhd 123-free medium. Each peak is identified by a 
fluorescence channel number and designates the amount of intracellular Rhd 123 in each sample in the absence and in 
presence of the tested compounds. 
 
3.4. Chemical stability test 
 
A stability study was performed to evaluate the actual concentration of compounds 8, 9, 10 and 13 
in phosphate buffer solution (PBS), human and rat plasma samples.  
The samples were analyzed by LC-MS/MS method operating in Multiple Reaction Monitoring 
(MRM) mode [38].
 
The solution stability of each studied compound was verified by monitoring the 
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variation of analyte concentration at different incubation times in phosphate buffer solution (PBS), 
human or rat plasma samples. Each set of samples was incubated at 37 °C in triplicate at four 
different times, 0, 30, 60 and 120 min. The human plasma batch was collected from a pool of 
healthy volunteers and the rat plasma batch was collected from a pool of Sprague Dawley male rats 
(see Experimental Section). The raw data processing and evaluation of calibration results are 
reported in Supplementary material.  
The obtained solution stability profiles showed that the concentrations of compounds 8, 9, 10 and 
13 did not varied until 120 min in the studied media (see Supplementary material). These data 
indicate that the solutions of compounds 8, 9, 10 and 13 were not susceptible to degradation in 
phosphate buffer solution (PBS), human or rat plasma samples. Moreover, the steady concentration 
of these compounds in human and rat plasma revealed that their available concentrations were not 
affected by high affinity plasma protein binding; this protein interaction could cause a loss of a 
fraction of analyte in the pellet precipitation during plasma proteins denaturation [39]. 
 
4. Conclusions  
 
A series of derivatives containing a piperazine scaffold 1,4-substituted with different arylalkyl 
groups on the two nitrogen atoms, were synthesized and evaluated for P-gp inhibitory activity on 
doxorubicin-resistant erythroleukemia K562 cell line (K562/DOX). These new compounds showed 
good P-gp modulating ability in the pirarubicin assay with potency values that are, in general, 
higher than that of the reference compound verapamil. The efficacy values (max) are in most cases 
close to 1, meaning that they can nearly completely reverse P-gp-dependent pirarubicin extrusion.  
The potency was positively influenced by the presence of methoxy groups in the arylalkyl residues, 
in fact, compounds 6-13, bearing methoxy aromatic moieties, were more potent than those with 
methoxy unsubstituted aromatic moieties (1-5). In particular, compounds 8, 9, 10 and 13 displayed 
an outstanding activity with [I]0.5 values in the nanomolar range. These compounds are 
characterized by the presence of the trimethoxy substituted arylalkyl groups g, h or m combined 
with a polyaryl group as l or f, on the two piperazine nitrogen atoms. The pharmacological profile 
of compounds 8, 9, 10 and 13 was further evaluated. Thus, compounds 8, 9, 10 and 13 were tested 
in the doxorubicin cytotoxicity enhancement test on K562/DOX cells, that revealed that they were 
able to restore the cytotoxicity of doxorubicin in a concentration-dependent manner. In particular, 
compounds 9 and 10 showed good reversal activities at 1.0 and 3.0 µM concentrations; in fact they 
were able to reduce the doxorubicin IC50 values by at least 10 times at 1.0 µM concentrations and 
by 44 times and 73 times-, respectively, at 3.0 µM concentrations. Also in the rhodamine-123 efflux 
test the most interesting compounds were 9 and 10 that were able to reduce the efflux of Rhd 123 
due to the P-gp transport activity, maintaining a high inhibition of the pump at least up to 60 min in 
Rhd 123-free medium.  
The solution stability profiles performed showed that these compounds were stable in phosphate 
buffer solution (PBS), human and rat plasma and that their available concentrations were not 
affected by high affinity plasma protein binding. Therefore, under the experimental conditions 
employed, their half-life values were estimated over 4 h. 
In summary, these studies suggest that the combination of a basic piperazine scaffold with aromatic 
residues, that characterized our previous lead compounds polymethylenic or cyclohexylic series, 
appears to be a fruitful approach. The presence of an alkylamine function in place of a potentially 
metabolic unstable ester function did not compromise the P-gp inhibitory activity of this series of 
compounds that were able to inhibit the P-gp pump with good potencies and efficacies; in fact, their 
activity values are within the same values of the most potent diester compounds of our previous 
series. The remarkable activity of derivatives with methoxy substituted arylalkyl moieties on the 
1,4-piperazine nitrogen atoms confirmed the positive influence of this hydrogen bond acceptor 
group on the P-gp modulation as it had been shown by the lead compounds and many well-known 
potent P-gp modulating compounds. Two long-lasting P-gp pump modulators were identified since 
14 
 
compounds 9 and 10 were able to inhibit remarkably the P-gp substrate rhodamine-123 efflux on 
the resistant K562/DOX cell line after 60 min. Among the piperazine derivatives evaluated in this 
study, compound 9 presented the best pharmacological profile since it had no intrinsic toxicity to 
the parental and resistant cell line, and showed a outstanding activity in all pharmacological assays. 
Moreover it showed a peculiar binding kinetics that allowed it to inhibit the P-gp extrusion activity 
in an noteworthy way even after 60 min. Further development of compound 9 could be promising to 
the identification of potent and long-lasting efficacious P-gp–dependent MDR modulators. 
 




All melting points were taken on a Büchi apparatus and are uncorrected. Infrared spectra were 
recorded with a Perkin-Elmer Spectrum RX I FT-IR spectrophotometer in Nujol mull for solids and 
neat for liquids. NMR spectra were recorded on a Bruker Avance 400 spectrometer (400 MHz for 
1
H NMR, 100 MHz for 
13
C NMR) using residual solvent such as chloroform (δ = 7.26) as internal 
standard. Chromatographic separations were performed on a silica gel column by gravity 
chromatography (Kieselgel 40, 0.063-0.200 mm; Merck) or flash chromatography (Kieselgel 40, 
0.040-0.063 mm; Merck). Yields are given after purification, unless otherwise stated. When 
reactions were performed in anhydrous conditions, the mixtures were maintained under nitrogen. 
The combustion analyses of compounds 1-13 are indicated by symbols, and the analytical results 
are within 0.4% of the theoretical values. ESI-MS spectra were obtained using a Varian 1200L 
triple quadrupole system (Palo Alto, CA, USA) equipped by Elettrospray Source (ESI) operating in 
both positive and negative ions. Except for compounds 3 and 4, the free bases form of the final 
compounds were transformed into the dihydrochloride by treatment with 2.2 eq of acetyl chloride in 
anhydrous CH3OH. The salts were crystallized from abs. ethanol/petroleum ether. Compounds were 
named following IUPAC rules as applied by ChemBioDraw Ultra 14.0 software. 
 
5.1.1. 5-(2-Bromoethoxy)-1,2,3-trimethoxybenzene 14 
To a solution of 3,4,5-trimethoxyphenol (1.0 g, 5.43 mmol) in anhydrous DMF, K2CO3 (6.76 g, 
48.90 mmol) and 1,2-dibromoethane (1.22 g, 6.38 mmol) were added. The mixture was heated to 60 
°C for 24 hours and then treated with a saturated solution of NaCl and extracted three times with 
ethyl acetate. After drying with Na2SO4, the solvent was removed under reduced pressure. The 
crude product was purified by flash chromatography using cyclohexane/ethyl acetate 7:3 as eluting 
system. The title compound (1.15 g, 75% yield) was obtained as a colorless oil. 
1
H NMR (CDCl3): δ 6.16 (s, 2H, arom.); 4.26 (t, J = 6.0 Hz, 2H, OCH2); 3.84 (s, 6H, OCH3); 3.78 
(s, 3H, OCH3); 3.62 (t, J = 6.0 Hz, 2H, CH2Br) ppm. 
 
5.1.2. General procedure for the synthesis of N-arylalkylpiperazine-N-carboxylic acid tert-butyl 
esters 15-19. 
To a 1 mmol portion of the appropriate arylalkyl halide (5-bromo-2-isopropyl-2-
phenylpentanenitrile [22], 2-bromoethoxy benzene [22], (E)-(3-bromoprop-1-enyl)benzene, 9-
(chloromethyl)anthracene [23] and 5-(2-bromoethoxy)-1,2,3-trimethoxybenzene (14). and 
anhydrous K2CO3 (1.2 mmol) in 5 mL of anhydrous CH3CN a solution of N-t-BOC-piperazine [21] 
(185 mg, 1 mmol) was added. The reaction mixture was heated at 60 °C for 5-6 h and stirred 
overnight at room temperature. Then the organic layer was washed three times with a saturated 
solution of NaHCO3. After drying with Na2SO4, the solvent was removed under reduced pressure. 
The substances obtained were purified by flash chromatography or used as such for the next 
reaction, in the case of 19. 
 
5.1.2.1  4-(4-Cyano-5-methyl-4-phenylhexyl)piperazine-1-carboxylic acid tert-butyl ester 15  
15 
 
Oil. Chromatographic eluent: abs EtOH/NH4OH/CH2Cl2/ethyl ether/petroleum ether 




H NMR (CDCl3) δ 
7.35 (d, J = 3.5 Hz, 4H, arom.); 7.28 (d, J = 3.0 Hz, 1H, arom.); 3.35 (s, 4H, CH2); 2.26-2.21 (m, 
6H, CH2); 2.16-2.08 (m, 3H, CH2-CHH); 1.93-1.87 (td, J = 8.0 Hz, J = 4.3 Hz, 1H, CHH); 1.54-
1.52 (m, 1H, CH); 1.42 (s, 9H, CH3); 1.18 (d, J = 6.7 Hz, 3H, CH3); 0.75 (d, J = 6.7 Hz, 3H, CH3) 
ppm. 
 
5.1.2.2. 4-(2-Phenoxyethyl)piperazine-1-carboxylic acid tert-butyl ester 16 





H NMR (CDCl3) δ 7.31-7.27 (m, 2H arom.); 6.98-6.91 (m, 3H arom.); 4.12 (t J = 5.7 Hz, 2H, 
CH2O,); 3.47 (s, 4H, CH2); 2.83 (t, J = 5.7 Hz, 2H, CH2N); 2.54 (s, 4H, CH2); 1.45-1.48 (s, 9H, 
CH3) ppm. 
 
5.1.2.3. 4-Cinnamylpiperazine-1-carboxylic acid tert-butyl ester 17 
Oil. Chromatographic eluent: abs EtOH/NH4OH/CH2Cl2/ethyl ether/petroleum ether 




H NMR (CDCl3) δ 7.39-7.33 (m, 
2H arom.); 7.32-7.26 (m, 2H arom.); 7.23-7.19 (m, 1H arom.); 6.52 (d, J = 15.8 Hz, 1H, CH=CH); 
6.30-6.21 (m, 1H, CH=CH); 3.46 (s, 4H, CH2); 3.15 (d, 2H, CH2N, J = 6.8 Hz); 2.44 (s, 4H, CH2); 
1.46 (s, 9H, CH3) ppm. 
 
5.1.2.4. Anthracen-9-ylmethylpiperazine-1-carboxylic acid tert-butyl ester 18 




H NMR (CDCl3): δ 8.48 
(s, 1H, arom.); 8.44 (d, J = 12.4 Hz, 2H, arom.); 8.01 (d, J = 8.0 Hz, 2H, arom.); 7.58-7.42 (m, 4H, 
arom.); 4.44 (s, 2H, CH2); 3.38 (bs, 4H, CH2); 2.57 (bs, 4H, CH2); 1.58-1.37 (m, 9H, CH3) ppm. 
 
5.1.2.5. 4-[2-(3,4,5-Trimethoxyphenoxy)ethyl]piperazine-1-carboxylic acid tert-butyl ester 19 





H NMR (CDCl3) δ: 6.14 (s, 2H, arom.); 4.05 (t, J = 5.6 Hz, 2H, OCH2); 3.82 (s, 6H, OCH3); 
3.77 (s, 3H, OCH3); 3.45 (t, J = 5.6 Hz, 4H, CH2); 2.78 (t, J = 6.0 Hz, 2H, CH2); 2.50 (t, J = 6.0 Hz, 
4H, CH2); 1.44 (s, 9H, CH3) ppm. 
 
5.1.2.6. (E)-4-[3-(3,4,5-Trimethoxyphenyl)allyl]piperazine-1-carboxylic acid tert-butyl ester 20 
A solution of 501.0 mg of (E)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-ol [25] (2.24 mmol) and 
anhydrous Et3N (0.37 mL, 2.68 mmol) in 6 mL of anhydrous CH2Cl2 was cooled to 0 °C and 
CH3SO2Cl (0.21 mL, 2.24 mmol) was added. The reaction mixture was stirred at 0 °C for 45 
minutes and then at room temperature for 3 hours. Then solid N-t-BOC-piperazine [21] (417.0 mg, 
2.24 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature and 
heated to 60 °C for 6 hours. Then the organic layer was washed three times with a saturated solution 
of NaHCO3. After drying with Na2SO4, the solvent was removed under reduced pressure. The crude 
product was purified by chromatography using CH2Cl2/MeOH 98:2 as eluting system. The title 





NMR (CDCl3): δ 6.57 (s, 2H, arom.); 6.41 (d, J = 16.0 Hz, 1H, CH=CH); 6.13 (dt, J = 16.0 Hz, 6.8 
Hz, 1H, CH=CH); 3.82 (s, 6H, OCH3); 3.80 (s, 3H, OCH3); 3.52-3.38 (m, 4H, CH2); 3.11 (d, J = 6.8 
Hz, 2H, CH2); 2.53-2.36 (m, 4H, CH2); 1.42 (s, 9H, CH3) ppm. 
  
5.1.3. General procedure for the synthesis of N-arylalkylpiperazines 21-26 
A 1 mmol portion of the suitable N-arylalkyl-piperazine-N-carboxylic acid tert-butyl esters (15-20) 
was dissolved in 10 ml of anhydrous CH2Cl2 and 2 mL of CF3COOH were added. The reaction 
mixture was stirred for 2 hours at room temperature. The solvent was removed under reduced 
pressure and the residue was washed three times with a saturated solution of NaHCO3. The organic 
16 
 
layer was dried with Na2SO4, and the solvent was removed under reduced pressure yielding a 
substance which was used as such for the next reaction. 
 
5.1.3.1. 4-(4-Cyano-5-methyl-4-phenylhexyl)piperazine 21 




H NMR (CDCl3): δ 7.26 (t, J = 6.4 
Hz, 4H, arom.); 7.20-7.16 (m, 1H, arom.); 2.73 (t, J = 4.7 Hz, 4H, CH2); 2.15 (t, J = 7.2 Hz, 6H, 
CH2); 2.09-2.01 (m, 2H, CH2); 1.96 (s, 1H, NH); 1.80 (td, J = 8.0 Hz, J = 4.4 Hz, 1H, CHH); 1.50-
1.42 (m, 1H, CHH); 1.10 (d, J = 6.8 Hz, 3H, CH3); 1.06-0.99 (m, 1H, CH); 0.67 (d, J = 6.8 Hz, 3H, 
CH3) ppm. 
 
5.1.3.2. 1-(2-Phenoxyethyl)piperazine 22 




H NMR (CDCl3): δ 7.31-7.24 (m, 2H, arom.); 6.96-
6.90 (m, 3H, arom.); 4.11 (t, J = 5.9 Hz, 2H, CH2O); 2.97-2.86 (m, 4H, CH2); 2.80 (t, J = 5.9 Hz, 
2H, CH2N); 2.55 (s, 4H, CH2); 1.83 (bs, 1H, NH) ppm. 
 
5.1.3.3. 1-Cinnamylpiperazine 23 




H NMR (CDCl3): δ 7.40-7.30 (m, 1H arom.); 7.31-
7.27 (m, 3H arom.); 7.24-7.19 (m, 1H arom.); 6.51 (d, J = 15.8 Hz, 1H, CH=CH); 6.31-6.22 (m, 1H, 
CH=CH); 3.14 (d, J = 5.64 Hz, 2H, CH2); 2.95-2.83 (m, 4H, CH2); 2.47 (s, 4H, CH2); 2.29 (bs, 1H, 
NH) ppm. 
 
5.1.3.4. 1-Anthracen-9-ylmethylpiperazine 24 




H NMR (CDCl3): δ 8.49 (d, J = 8.8 Hz, 2H, 
arom.); 8.42 (s, 1H, arom.); 8.00 (d, J = 8.0 Hz, 2H, arom.); 7.58-7.42 (m, 4H, arom.); 4.42 (s, 2H, 
CH2); 2.82 (t, J = 4.8 Hz, 4H, CH2); 2.72-2.52 (m, 4H, CH2); 2.14 (bs, 1H, NH) ppm. 
 
5.1.3.5. 1-[2-(3,4,5-Trimethoxyphenoxy)ethyl]piperazine 25 




H NMR (CDCl3): δ 6.12 (s, 
2H, arom.); 4.04 (t, J = 5.6 Hz, 2H, OCH2); 3.80 (s, 6H, OCH3); 3.74 (s, 3H, OCH3); 2.89 (t, J = 5.6 
Hz, 4H, CH2); 2.79 (t, J = 5.6 Hz, 2H, NCH2); 2.52 (bs, 4H, CH2); 2.02 (bs, 1H, NH) ppm. 
 
5.1.3.6. (E)-1-[3-(3,4,5-Trimethoxyphenyl)allyl]piperazine 26 




H NMR (CDCl3): δ 6.59 (s, 2H, 
arom.); 6.43 (d, J = 16.0 Hz, 1H, CH=CH); 6.17 (dt, J = 16.0 Hz, J = 6.8 Hz, 1H, CH=CH); 3.85 (s, 
6H, OCH3); 3.82 (s, 3H, OCH3); 3.12 (d, J = 6.8 Hz, 2H, CH2); 3.00-2.79 (m, 4H, CH2); 2.48 (bs, 
4H, CH2); 2.18 (bs, 1H, NH) ppm. 
 
5.1.4. General procedure for the synthesis of N,N-bis(arylalkyl)piperazines 1-13 
To a mixture of a 1 mmol portion of the suitable N-arylalkylpiperazine (21-27) and anhydrous 
K2CO3 (1.2 mmol), the appropriate arylalkyl halide (1 mmol) ((E)-(3-bromoprop-1-enyl)benzene, 2-
bromo-ethoxy benzene [22], 1-bromo-4,4-diphenylbutane [27], 1-bromo-4,4-bis(4-
fluorophenyl)butane [28], 5-bromo-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile [29], 1-
bromo-4,4-bis(4-methoxyphenyl)butane [30], 5-(chloromethyl)-1,2,3-trimethoxybenzene [31], 9-
(chloromethyl)anthracene [23]) dissolved in 5 mL of anhydrous CH3CN, was added. The reaction 
mixture was heated at 60 °C for 5-6 h and stirred overnight at room temperature. Then CH2Cl2 was 
added and the organic layer was washed three times with a saturated solution of NaHCO3. After 
drying with Na2SO4, the solvent was removed under reduced pressure. The crude product was then 
purified by flash chromatography using the appropriate eluting system, yielding the desired 
compound as an oil or solid. The compounds were transformed into the corresponding 





5.1.4.1. 5-(4-Cinnamylpiperazin-1-yl)-2-isopropyl-2-phenylpentanenitrile 1 




H NMR (CDCl3): δ 7.38 (t, J = 3.5 Hz, 5H, arom.); 7.34-7.22 (m, 5H, arom.); 6.53 (d, J = 15.8 Hz, 
1H, CH=CH); 6.31-6.24 (m, 1H, CH=CH); 3.16 (d, J = 6.7 Hz, 2H, CH2); 2.50 (bs, 4H, CH2); 2.40 
(bs, 4H, CH2); 2.30 (t, J = 7.0 Hz, 2H, CH2); 2.20-2.10 (m, 2H, CH2); 1.91 (td, J = 8.0 Hz, J = 4.5 
Hz, 1H, CHH); 1.60-1.54 (m, 1H, CHH); 1.22 (d, J = 6.7 Hz, 3H, CH3); 1.18-1.13 (m, 1H, CH); 
0.79 (d, J = 6.7 Hz, 3H, CH3) ppm. 
13
C NMR (CDCl3): δ 138.14 (CH2); 136.85 (C); 133.31 (CH); 
128.74 (CH arom.); 128.65 (CH arom.); 128.57 (CH arom.); 126.35 (CH arom.); 126.17
 
(CH); 
121.21 (C); 60.92 (C); 57.79 (C); 53.72 (CH2); 52.91 (CH2); 37.73 (CH); 35.47 (CH2); 22.18 (CH2); 
18.95 (CH3); 18.61 (CH3). Dihydrochloride. Mp: 234-235 °C. Anal: C27H37Cl2N3 (C, H, N). 
 
5.1.4.2. 2-Isopropyl-5-(4-(2-phenoxyethyl)piperazin-1-yl)-2-phenylpentanenitrile 2 




H NMR (CDCl3): δ 7.38-7.26 (m, 7H, arom.); 6.97-6.90 (m, 3H, arom.); 4.10 (t, J = 5.9 Hz, 2H, 
CH2); 2.80 (t, J = 5.9 Hz, 2H, CH2); 2.60 (bs, 4H, CH2); 2.40 (bs, 4H, CH2); 2.31-2.20 (m, 2H, 
CH2); 2.19-2.10 (m, 2H, CH2); 1.91 (td, J = 8.0 Hz, J = 4.4 Hz, 1H, CHH); 1.60-1.53 (m, 1H, 
CHH); 1.22 (d, J = 6.7 Hz, 3H, CH3); 1.18-1.12 (m, 1H, CH); 0.79 (d, J = 6.7 Hz, 3H, CH3) ppm.
 
13
C NMR (CDCl3): δ 138.00 (C); 129.45 (CH arom.); 128.79 (CH arom.); 127.66 (CH arom.); 
126.36 (CH arom.); 121.17 (CN); 120.90 (CH arom.); 114.58 (CH arom.); 65.53 (CH2); 57.54 (C); 
56.97 (C); 53.68 (CH2); 52.97 (CH2N); 52.95 (CH2); 37.74 (CH); 35.34 (CH2); 22.52 (CH2); 18.95 
(CH3); 18.61 (CH3) ppm. Dihydrochloride. Mp: 208-212°C. Anal: C26H37Cl2N3O (C, H, N).  
  
5.1.4.3. 1-(4,4-Diphenylbutyl)-4-(2-phenoxyethyl)piperazine 3 
Free base: chromatographic eluent: abs. EtOH./NH4OH/CH2Cl2/ethyl ether/petroleum ether 
180:9.9:360:360: 900. Mp: 75-77°C. Yield: 50%. 
1
H NMR (CDCl3): δ 7.32-7.26 (m, 10H, arom.); 
7.21-7.17 (m, 2H arom.); 6.99-6.92 (m, 3H arom.); 4.13 (t, J = 5.9 Hz, 2H, CH2O); 3.93 (t, J = 7.8 
Hz, 1H, CH); 2.84 (t, J = 5.9 Hz, 2H, CH2); 2.63 (bs, 4H, CH2); 2.48 (bs, 4H, CH2); 2.40 (t, J = 7.5 
Hz, 2H, CH2); 2.10 (q, J = 7.8 Hz, 2H, CH2); 1.52-1.47 (m, 2H, CH2) ppm. 
13
C NMR (CDCl3): δ 
158.77 (C); 145.04 (C); 129.45 (CH arom.); 128.44 (CH arom.); 127.86 (CH arom.); 126.12 (CH 
arom.); 120.80 (CH arom.); 114.62 (CH arom.); 65.79 (CH2); 58.55 (CH2); 57.25 (CH2); 53.62 
(CH2N); 53.14 (CH2N); 51.36 (CH); 33.61 (CH2); 25.38 (CH2) ppm. Anal: C28H34N2O (C, H, N). 
 
5.1.4.4. 1-Cinnamyl-4-(4,4-diphenylbutyl)piperazine 4 
Free base: chromatographic eluent: CHCl3/MeOH 95:5. Mp: 105-107 °C. Yield: 56%. 
1
H NMR 
(CDCl3): δ 7.42-7.38 (m, 2H arom.); 7.37-7.26 (m, 11H arom.); 7.22-7.18 (m, 2H arom.); 6.58-6.56 
(d, J = 15.9 Hz, 1H, CH=CH); 6.35-6.28 (m, 1H, CH=CH); 3.94 (t, J = 7.8 Hz, 1H, CH); 3.19 (d, J 
= 6.8 Hz, 2H, CH2); 2.50 (bs, 6H, CH2); 2.41 (t, J = 7.5 Hz, 4H, CH2); 2.10 (q, J = 7.8 Hz, 2H, 
CH2); 1.55-1.47 (m, 2H, CH2) ppm. 
13
C NMR (CDCl3): δ 145.04 (C); 136.96 (C); 133.08 (CH); 
128.57 (CH arom.); 128.43 (CH arom.); 127.86 (CH arom.); 127.49 (CH); 126.59 (CH arom.); 
126.33 (CH arom.); 126.11 (CH arom.); 61.08 (CH2); 58.56 (CH2); 53.19 (CH2N); 51.36 (CH); 
33.63 (CH2); 25.40 (CH2) ppm. Anal: C29H34N2 (C, H, N). 
 
5.1.4.5. 1-(4,4-Bis(4-fluorophenyl)butyl)-4-cinnamylpiperazine 5  
Free base: chromatographic eluent: CHCl3/MeOH 95:5.Yield: 56%. 
1
H-NMR (CDCl3): δ 7.41-7.37 
(m, 2H arom.); 7.35-7.28 (m, 2H arom.); 7.26-7.23 (m, 1H arom.); 7.20-7.16 (m, 4H arom.); 7.01-
6.96 (m, 4H arom.); 6.54 (d, J = 15.8 Hz, 1H, CH=CH); 6.33-6.26 (m, 1H, CH=CH); 3.89 (t, J = 7.7 
Hz, 1H, CH); 3.18 (d, J = 6.8 Hz, 2H, CH2); 2.55-2.48 (bs, 6H, CH2); 2.39 (t, J = 7.4 Hz, 4H, 
2CH2); 2.02 (q, J = 7.8 Hz, 2H, CH2); 1.47 (q, J = 8.0 Hz, 2H, CH2) ppm. 
13
C NMR (CDCl3): δ 
161.35 (d, J = 243 Hz, CF); 140.53 (C); 136.94 (C); 133.08 (CH); 129.10 (d, J = 7 Hz, CHF); 
128.57 (CH arom.); 127.50 (CH); 126.57 (CH arom.); 126.32 (CH arom.); 115.26 (d, CHF, J = 21 
18 
 
Hz); 61.06 (CH2); 58.45 (CH2); 53.20 (CH2-N); 49.76 (CH); 33.84 (CH2); 25.31 (CH2) ppm. 
Dihydrochloride. Mp: 244-248 °C. Anal: C29H34Cl2F2N2 (C, H, N).  
 
5.1.4.6. (E)-2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-{4-[3-(3,4,5-trimethoxyphenyl)allyl]piperazin-
1-yl}pentanenitrile 6  





H NMR (CDCl3): δ 6.92-6.90 (m, 1H, arom.); 6.89 (s, 2H, arom.); 6.59 (s, 2H, arom.); 
6.42 (d, J = 16.0 Hz, 1H, CH=CH); 6.17 (dt, J = 16.0 Hz, J = 6.8 Hz, 1H, CH=CH); 3.91-3.82 (m, 
15H, OCH3); 3.12 (d, J = 6.8 Hz, 2H, CH2); 2.65-2.32 (m, 8H, CH2); 2.29 (t, J = 7.2 Hz, 2H, CH2); 
2.18-2.02 (m, 2H, CH2); 1.81-1.70 (m, 2H, CH2); 1.49-1.62 (m, 1H, CH); 1.18 (d, J = 6.4 Hz, 3H, 
CH3); 0.78 (d, J = 6.8 Hz, 3H, CH3) ppm.
 13
C NMR (CDCl3): δ 153.29 (C); 149.03 (C); 148.30 (C); 
132.61 (CH); 132.59 (C); 130.65 (C); 126.07 (C=C); 121.35 (C); 118.69 (CH arom.); 111.14 (CH 
arom.); 109.58 (CH arom.); 103.35 (CH arom.); 60.88 (OCH3); 60.88 (CH2); 57.92 (CH2); 56.03 
(OCH3); 56.01 (OCH3); 55.99 (OCH3); 55.90 (OCH3); 53.37 (C); 53.13 (CH2); 53.02 (CH2); 37.84 
(CH); 35.68 (CH2); 22.93 (CH2); 18.96 (CH3); 18.59 (CH3) ppm. Dihydrochloride. Low melting 









H-NMR (CDCl3): δ 6.94-6.87 (m, 1H, arom.); 6.86-6.78 (m, 2H, arom.); 6.14 (s, 2H, 
arom.); 4.02 (t, J = 6.0 Hz, 2H, OCH2); 3.87 (s, 3H, OCH3); 3.86 (s, 3H, OCH3); 3.81 (s, 6H, 
OCH3); 3.76 (s, 3H, OCH3); 2.75 (t, J = 6.0 Hz, 2H, CH2); 2.55 (bs, 4H, CH2); 2.37 (bs, 4H, CH2); 
2.27 (t, J = 7.2 Hz, 2H, CH2); 2.14-1.77 (m, 4H, CH2); 1.54-1.23 (m, 1H, CH); 1.15 (d, J = 3.4 Hz, 
3H, CH3); 0.77 (d, J = 3.4 Hz, 3H, CH3) ppm. 
13
C NMR (CDCl3): δ 155.38 (C); 153.67 (C); 149.02 
(C); 148.30 (C); 130.65 (C); 121.37 (CN); 118.71 (CH arom.); 111.12 (CH arom.); 109.53 (CH 
arom.); 92.36 (CH arom.); 66.15 (OCH2); 61.01 (OCH3); 57.93 (CH2N); 57.21 (NCH2); 56.08 
(OCH3); 55.99 (OCH3); 53.59 (CH2); 53.38 (CCN); 52.99 (CH2); 37.86 (CH); 35.76 (CH2); 22.95 
(CH2); 18.97 (CH3); 18.61 (CH3) ppm. Dihydrochloride. Mp: 90-92 °C. Anal: C31H47Cl2N3O6 (C, 
H, N).    
 
5.1.4.8. 1-[4,4-Bis-(4-methoxyphenyl)-butyl]-4-[2-(3,4,5-trimethoxyphenoxy)ethyl]piperazine 8 
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH 95:5:0.5. Yield: 73%. 
1
H-NMR 
(CDCl3): δ 7.14 (d, J = 4.4 Hz, 4H, arom.); 6.80 (d, J = 4.4 Hz, 4H, arom.); 6.15 (s, 2H, arom.); 4.05 
(t, J = 7.6 Hz, 2H, OCH2); 3.82 (s, 7H, CH and OCH3); 3.78 (s, 3H, OCH3); 3.75 (s, 6H, OCH3); 
2.78 (t, J = 6.8 Hz, 2H, CH2); 2.58 (bs, 4H, CH2); 2.44 (bs, 4H, CH2); 2.35 (t, J = 6.8 Hz, 2H, CH2); 
2.04-1.92 (m, 2H, CH2); 1.52-1.48 (m, 2H, CH2) ppm. 
13
C NMR (CDCl3): δ 157.81 (C); 155.42 
(C); 153.68 (C); 137.60 (C); 128.62 (CH arom.); 113.79 (CH arom.); 92.39 (CH arom.); 66.15 
(OCH2); 61.02 (OCH3); 58.58 (CH2N); 57.25 (CH2N); 56.09 (OCH3); 55.22 (OCH3); 53.66 (CH2); 
53.14 (CH2); 49.58 (CH); 33.95 (CH2); 25.42 (CH2) ppm. Dihydrochloride. Mp: 161-163 °C. Anal: 
C33H46Cl2N2O6 (C, H, N). 
 
5.1.4.9. (E)-1-[4,4-Bis-(4-methoxyphenyl)butyl]-4-[3-(3,4,5-trimethoxyphenyl)allyl]piperazine 9 
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH 95:5:0.5. Yield: 60%. 
1
H-NMR 
(CDCl3): δ 7.12 (d, J = 8.8 Hz, 4H, arom.); 6.84 (d, J = 8.8 Hz, 4H, arom.); 6.60 (s, 2H, arom.); 6.43 
(d, J = 15.6 Hz, 1H, CH=CH); 6.19 (dt, J = 15.6 Hz, 6.8 Hz, 1H, CH=CH); 3.85 (s, 6H, OCH3); 
3.83 (s, 3H, OCH3); 3.78-3.82 (m, 1H, CH); 3.75 (s, 6H, OCH3); 3.13 (d, J = 6.8 Hz, 2H, CH2); 
2.47 (bs, 8H, CH2); 2.36 (t, J = 7.6 Hz, 2H, CH2); 2.05-1.93 (m, 2H, CH2); 1.58-1.48 (m, 2H, CH2) 
ppm.
 13
C NMR (CDCl3): δ 157.81 (C); 133.31 (C); 137.60 (C); 132.88 (C=C); 132.66 (C); 128.61 
(CH arom.); 126.22 (C=C); 113.78 (CH arom.); 103.34 (CH arom.); 60.96 (OCH3); 60.92 (CH2); 
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58.59 (CH2); 55.21 (OCH3); 53.24 (OCH3); 53.24 (CH2); 53.19 (CH2); 49.58 (CH); 33.97 (CH2); 
25.42 (CH2) ppm. Dihydrochloride. Mp: 101-103 °C. Anal: C34H46Cl2N2O5 (C, H, N).  
 
5.1.4.10. 1-[4,4-Bis(4-methoxyphenyl)butyl]-4-(3,4,5-trimethoxybenzyl)piperazine 10 
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH 97:3:0.3. Yield: 52%. 
1
H-NMR 
(CDCl3): δ 7.12 (d, J = 8.4 Hz, 4H, arom.); 6.80 (d, J = 8.4 Hz, 4H, arom.); 6.55 (s, 2H, arom.); 3.85 
(s, 6H, OCH3); 3.83 (s, 3H, OCH3); 3.80 (t, J = 8.0 Hz, 1H, CH); 3.75 (s, 6H, OCH3); 3.42 (s, 2H, 
CH2); 2.44 (bs, 6H, CH2); 2.38-2.29 (m, 4H, CH2); 2.03-1.94 (m, 2H, CH2); 1.49-1.38 (m, 2H, CH2) 
ppm. 
13
C NMR (CDCl3): δ 157.80 (C); 153.06 (C); 137.51 (C); 136.87 (C); 134.05 (C); 128.61 (CH 
arom.); 113.78 (CH arom.); 105.83 (CH arom.); 63.28 (CH2); 60.85 (OCH3); 58.64 (CH2); 56.13 
(OCH3); 55.22 (OCH3); 53.26 (CH2); 53.11 (CH2); 49.57 (CH); 34.00 (CH2); 25.45 (CH2) ppm. 
ESI-MS: 535.4[M+H]
+
. Dihydrochloride. Mp: 249-251 (dec) °C. Anal: C32H44Cl2N2O5 (C, H, N). 
   
5.1.4.11. 1-Anthracen-9-ylmethyl-4-[4,4-bis(4-methoxyphenyl)butyl]piperazine 11 
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH 99:1:0.1. Yield: 20%. 
1
H NMR 
(CDCl3): δ 8.48 (d, J = 8.8 Hz, 2H, arom.); 8.41 (s, 1H, arom.); 8.00 (d, J = 8.0 Hz, 2H, arom.); 
7.61-7.40 (m, 4H, arom.); 7.12 (d, J = 6.8 Hz, 4H, arom.); 6.80 (d, J = 6.8 Hz, 4H, arom.); 4.43 (s, 
2H, CH2); 3.88-3.66 (m, 7H, CH and OCH3); 2.65 (bs, 4H, CH2); 2.50-2.22 (m, 6H, CH2); 2.08-
1.90 (m, 2H, CH2); 1.52-1.39 (m, 2H, CH2) ppm. 
13
C NMR (CDCl3): δ 157.87 (C); 137.67 (C); 
131.46 (C); 129.86 (C); 128.99 (CH arom.); 128.67 (CH arom.); 127.44 (CH arom.); 125.62 (CH 
arom.); 125.22 (CH arom.); 124.91 (CH arom.); 113.84 (CH arom.); 58.54 (CH2); 55.25 (OCH3); 
54.32 (CH2); 53.37 (CH2); 53.21 (CH2); 49.59 (CH); 33.98 (CH2); 25.39 (CH2) ppm. 
Dihydrochloride. Mp: 120-122 °C. Anal: C37H42Cl2N2O2 (C, H, N). 
 
5.1.4.12. (E)-1-(3,4,5-Trimethoxybenzyl)-4-[3-(3,4,5-trimethoxyphenyl)allyl]piperazine 12 
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH 98:2:0.2. Yield: 61%. 
1
H NMR 
(CDCl3): δ 6.58 (s, 2H, arom.); 6.54 (s, 2H, arom.); 6.42 (d, J = 15.6 Hz, 1H, CH=CH); 6.18 (dt, J = 
15.6 Hz, J = 6.8 Hz, 1H, CH=CH); 3.90-3.75 (m, 18H, OCH3); 3.44 (s, 2H, CH2); 3.15 (d, J = 6.4 
Hz, 2H, CH2); 2.52 (bs, 8H, CH2) ppm.
 13
C NMR (CDCl3): δ 153.31 (C); 153.09 (C); 137.82 (C); 
137.00 (C); 133.78 (C); 133.02 (CH); 132.59 (C); 126.00 (CH); 105.91 (CH arom.); 103.40 (CH 
arom.); 63.16 (CH2); 60.90 (CH2); 60.81 (OCH3); 56.13 (OCH3); 55.04 (OCH3); 53.20 (CH2); 52.96 
(CH2) ppm. Dihydrochloride. Mp: 87 (dec) °C. Anal: C26H38Cl2N2O6 (C, H, N). 
 
5.1.4.13. (E)-1-Anthracen-9-ylmethyl-4-[3-(3,4,5-trimethoxyphenyl)allyl]piperazine 13 
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH 98:2:0.2. Yield: 35%. 
1
H NMR 
(CDCl3): δ 8.48 (d, J = 8.8 Hz, 2H, arom.); 8.41 (s, 1H, arom.); 8.00 (d, J = 8.4 Hz, 2H, arom.); 
7.68-7.40 (m, 4H, arom.); 6.59 (s, 2H, arom.); 6.41 (d, J = 16.0 Hz, 1H, CH=CH); 6.21 (dt, J = 16.0 
Hz, J = 6.4 Hz, 1H, CH=CH); 4.47 (s, 2H, CH2); 3.85 (s, 6H, OCH3); 3.84 (s, 3H, OCH3); 3.15 (d, J 
= 6.8 Hz, 2H, CH2); 2.72 (bs, 4H, CH2); 2.52 (bs, 4H, CH2) ppm.
 13
C NMR (CDCl3): δ 153.32 (C); 
133.25 (CH); 132.53 (C); 131.40 (C); 129.55 (C); 128.96 (CH arom.); 127.47 (CH arom.); 125.62 
(CH); 125.07 (CH arom.); 124.86 (CH arom.); 103.43 (CH arom.); 60.92 (OCH3); 60.75 (CH2); 
56.07 (OCH3); 54.18 (CH2); 53.25 (CH2); 52.97 (CH2) ppm. Dihydrochloride. Mp: 90 (dec) °C. 




5.2.1. Cell lines and cultures.  
K562 is an undifferentiated erythroleukemia cell line originally derived from a patient with 
chronic myelogenous leukemia [35]. The K562 leukemia cells and the P-gp over-expressing 
K562/DOX cells were obtained from Prof. J.P. Marie (Hopital Hotel-Dieu, Paris, France). These 




5.2.2. Modulation of pirarubicin uptake.  
Purified pirarubicin and verapamil were provided by Sigma-Aldrich (Milan-Italy). 
Concentrations were determined by diluting stock solutions to approximately 10
-5





. Stock solutions were prepared just before use. Buffer solutions were HEPES 
buffer containing 5 mM HEPES, 132 mM NaCl, 3.5 mM CaCl2, 5 mM glucose, at pH 7.3. 
The uptake of pirarubicin in cells was followed by monitoring the decrease in the fluorescence 
signal at 590 nm (ex = 480 nm) according to the previously described method [40,41]. 
 
5.2.3. Effects on doxorubicin cytotoxicity.  
Doxorubicin hydrochloride (DOX), verapamil, dimethylsulphoxide (DMSO) and 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich 
(Milan-Italy). Tariquidar was purchased from Medchemexpress Europe (Stockholm SWEDEN). 
MTT stock solution was prepared following the previously described method [16].
 
Tested 
compounds and tariquidar solutions were prepared in DMSO at 10
-2 
M, DOX stock, verapamil 
solutions were prepared in water at 10
-2 
M. Drugs and studied compounds were then diluted with 
complete medium to obtain the 10x desired final maximum test concentrations. Verapamil and 
tariquidar were used as standard P-gp modulators and were evaluated at 3 and 1 M concentrations, 
respectively. 
To evaluate the reversing activity of the tested compounds, the cells, in exponential growth phase 
(3x10
5 
cells/mL), were seeded at 10
4 
cells/well and either tested compounds solutions or 
doxorubicin solution or combination of a solution of doxorubicin and tested compounds were added 
to the wells and the plates were incubated at 37 °C for 72 h in 5% CO2  incubator. The compounds 
were evaluated for MDR reversal activity at 0.1, 1.0 and 3.0 M and the corresponding doxorubicin 
concentrations tested were between 0.0001 and 100 M. The MTT working solution was added and 
plates were further incubated for 3 h. Following incubation cells and formazan crystals were 
inspected microscopically. The supernatant was then carefully removed by slow aspiration and the 
formazan crystals were dissolved in 150 L of acidified isopropanol solution. The absorbance of the 
solution was then read on an automated plate reader at a wavelength of 570 nm. 
The potency of the MDR reversers was expressed by the reversal fold (RF) values obtained as the 
ratio between the doxorubicin IC50 values on K562/DOX cells in the absence and in the presence of 
modulators.  
 
5.2.4. Inhibition of P-gp-mediated rhodamine-123 (Rhd123) efflux 
P-gp activity was evaluated by measuring the efflux of the P-gp substrate rhodamine 123 (Rhd 123), 
in K562/DOX cells, in the absence or in the presence of compounds 8, 9, 10 and 13, following a 
previously described method with minor modification [20]. Briefly, cells were loaded with 5.0 µM 
rhodamine 123 for 30 min at 37 °C in a humidified atmosphere of 5% CO2, with or without 
(control) tested compounds at 1.0 µM. All compounds were added 15 min before rhodamine-123. 
After the accumulation period of 30 min, the cells were washed and suspended in Rhd 123-free 
medium with or without compounds 8, 9, 10 and 13 at 1.0 µM concentration and reference 
compound verapamil at 3.0 µM concentration, for the efflux measures. 
The efflux was carried out for different times, 30 and 60 min, at 37 °C in 5% CO2. At the end of 
each efflux period, cells were sedimented, washed twice with ice-cold phosphate buffer saline 
(PBS) and placed in PBS on ice, and kept in the dark until flow cytometric analysis. Samples were 
analyzed on a FACSCanto flow cytometer (Becton Dickinson, san Jose CA,USA) equipped with 
488 and 633 nm lasers and FACSDIVA software. Samples were gated on forward scatter versus 
side scatter to exclude cell debris and at least 20,000 events were acquired; the green fluorescence 
of Rhd 123 was collected after a 530 nm band pass filter. Data were analyzed by FCS Express (De 
Novo Software). For each sample, the intracellular amount of Rhd 123 after the efflux times was 
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expressed by the mean fluorescence intensity (MFI) ratio obtained as the ratio between the median 
fluorescence intensity value of samples treated with Rhd 123 and modulators, and the control 
sample. The histograms were generated by program GraphPad Prism 5 (GraphPad Prism software, 
Inc. CA).  
 
5.3. Statistical analysis.  
All experiments were carried out in triplicate or quadruplicate and were independently done at 
least three times. All results are presented as means  SE and statistical analysis was performed 
using the one-way Anova test and Bonferroni’s multiple comparison test (GraphPad Prism 
software, Inc. CA, USA). 
 
5.4. Chemical stability tests 
 
5.4.1. Materials and methods 
5.4.1.1. Chemicals  
Acetonitrile (Chromasolv), formic acid and ammonium formate (MS grade), NaCl, KCl, Na2HPO4 
2H2O, KH2PO4 (Reagent grade) and verapamil hydrochloride (analytical standard, used as internal 
standard), ketoprofen and enalapril (analytical standard) were purchased by Sigma-Aldrich (Milan, 
Italy). Ketoprofen Ethyl Ester (KEE) were obtained by Fisher's reaction from ketoprofen and 
ethanol.  
MilliQ water 18 MΩ was obtained from Millipore's Simplicity system (Milan - Italy).  
Phosphate buffer solution (PBS) was prepared by adding 8.01 g L
-1
 of NaCl, 0.2 g L
-1
 of KCl, 1.78 
g L
-1
 of Na2HPO4 2H2O and 0.27 g L
-1
 of KH2PO4. Human plasma was collected from healthy male 




The LC-MS/MS analysis was carried out using a Varian 1200L triple quadrupole system (Palo Alto, 
CA, USA) equipped by two Prostar 210 pumps, a Prostar 410 autosampler and an Elettrospray 
Source (ESI) operating in positive ions. Raw-data were collected an processed by Varian 
Workstation Vers. 6.8 software. 
G-Therm 015 thermostatic oven was used to maintained the samples at 37 °C during the test of 
degradation. ALC micro centrifugette 4214 was employed to centrifuge plasma samples. 
 
5.4.2. Preparation of samples 
Each sample was prepared adding 10 μL of working solution 1 to 100 μL of tested matrix (PBS or 
rat plasma or human plasma) in microcentrifuge tubes. The obtained solutions correspond to 1 μM 
of analyte.  
Each set of samples was incubated in triplicate at four different times, 0, 30, 60 and 120 min at 37 
°C. Therefore the degradation profile of each analyte was represented by a batch of 12 samples (4 
incubation times x 3 replicates). After the incubation, the samples were added with 300 μL of ISTD 
solution and centrifuged (room temperature for 5 min at 10000 rpm). The supernatants were 
transferred in autosampler vials and dried under a gentle stream of nitrogen. 
The dried samples were dissolved in 1.0 mL of 10 mM of formic acid in mQ water:acetonitrile 
80:20 solution. The obtained sample solutions were analysed by LC-MS/MS method described in 
Supplementary material. 
The hydrolytic activity of human and rat plasma batches were checked using ketoprofene ethylester 
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